Comprehensive evaluation on the efficacy of Pramipexole in Early Parkinson 's Disease

Objective:To evaluate the efficacy of Pramipexole in Early Parkinson's Disease Comprehensively. Methods:60 early PD patients were randomly assigned to receive Madopar(n=30)or pramipexole alone(n=30). Parkinson diseases rating scale I-Ⅲ(UPDRS I-Ⅲ),H-Y staging, 24-items of Hamilton Rating Scale for Depression(HAMD-24), Hamilton Rating Scale for Anxiety(HAMA-14),Parkinson Disease Sleep Scale(PDSS),Fatigue Severity Scale(FSS),Scales for Outcomes in Parkinson's Disease-AUT(SCOPA-AUT), mini mental state examination(MMSE)and Questionnaire of non-motor symptoms in patients with PD were performed to estimate the degree of patient's motor symptoms and non—motor symptoms in all follow up windows; and analyze the motor fluctuation incidence, movement disorders incidence, non-motor symptom incidence and the adverse reactions incidence with statistics. Results:Compared to the baseline levels,the scores of UPDRS II,UPDRSⅢand H-Y staging in the Madopar group and the score of UPDRSⅢ in the pramipexole group were significantly improved in all follow up windows(P0.05),and the scores of UPDRS II and H-Y staging were significantly improved in the pramipexole group at the end of 1st year(P0.05), the scores of UPDRSⅢand H-Y staging in the Madopar group were significantly lower than those in the pramipexole group at the end of 1st and 2nd year(P0.05).The motor of fluctuation incidence and the non-motor symptom incidence in the Madopar group were significantly higher than those in the pramipexole group at the end of 2nd year(P0.05).The scores of UPDRS I, HAMD-24, HAMA-14,PDSS,FSS and SCOPA-AUT were significantly improved in all follow up windows(P0.05),but no significant difference was found in the Madopar group compared to the baseline levels. Incidence of drowsiness, visual hallucination and orthostatic hypotension in the pramipexole group were significantly higher than those in the Madopar group at the end of 2nd year. Conclusion:Pramipexole and Madopar can improve the motor symptom in Early Parkinson's Disease. Madopar may be superior to Pramipexole in terms of improvement of motor symptoms,but Pramipexole can delay the occurrence of motor complications and can improve some non-motor symptoms.